2-{[(1R,4aR,7R,8aR)-7-(2-羟基丙烷-2-基)-1,4a-二甲基十氢萘-1-基]氧代}-4-(丙-2-烯-1-基)-6-[4-(丙-2-烯-1-基)苯氧基]苯酚 | 125196-77-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 2-{[(1R,4aR,7R,8aR)-7-(2-羟基丙烷-2-基)-1,4a-二甲基十氢萘-1-基]氧代}-4-(丙-2-烯-1-基)-6-[4-(丙-2-烯-1-基)苯氧基]苯酚
• 英文名称: eudesobovatol A
• 英文别名: 2-[[(1R,4aR,7R,8aR)-7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-2,3,4,5,6,7,8,8a-octahydronaphthalen-1-yl]oxy]-4-prop-2-enyl-6-(4-prop-2-enylphenoxy)phenol
• CAS: 125196-77-2
• 化学式: C₃₃H₄₄O₄
• 分子量: 504.71
• InChiKey: JKKWXFYURXPBFN-CLRSYFRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.6
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-{[(1R,4aR,7R,8aR)-7-(2-羟基丙烷-2-基)-1,4a-二甲基十氢萘-1-基]氧代}-4-(丙-2-烯-1-基)-6-[4-(丙-2-烯-1-基)苯氧基]苯酚 在 三氟乙酸 作用下， 以 苯 为溶剂， 反应 10.0h， 以2 mg的产率得到2-[(2R,4aR)-4a,8-二甲基-2,3,4,5,6,7-六氢-1H-萘-2-基]丙-2-醇
  参考文献：
  名称：

  Neurotrophic sesquiterpene-neolignans from magnolia obovata: structure and neurotrophic activity

  摘要：

  Novel sesquiterpene-neolignans, audesobovatols A (1) and B (2) cudesmagnolol (3), eudeshonokiols A (4) and B (5), clovanemagnolol (6), and caryolanemagnolol (7), have been isolated from the bark of Magnolia obovata. Their structures were elucidated to be sesquiterpenes (eudesmol, 4,4,8-trimethyltricyclo [6.3.1.0(2,5)] dodecane-1,9-diol, and clovanediol) combined through ether bond with neolignans such as obovatol, honokiol, and magnolol on the basis of spectral data, degradation, and/or synthesis. Compounds I, 6, and 7 were found to exhibit interesting neurotrophic activity on a neuronal cell culture system derived from fetal rat hemisphere.

  DOI：

  10.1016/s0040-4020(01)89002-5

文献信息

• Hair composition
  申请人：Conopco, Inc.

  公开号：US10456344B2

  公开（公告）日：2019-10-29

  Disclosed is an oral or topical composition comprising a nuclear factor erythroid-2 related factor 2 agonist and a liver X receptor agonist, wherein the amounts of each of the nuclear factor erythroid-2 related factor 2 agonist and the liver X receptor agonist produce a synergistic benefit of hair fiber growth, wherein the oral or topical composition comprises ≤9, preferably ≤8% w/w β-sitosterol, wherein when the oral or topical composition comprises a catechin, the oral or topical composition comprises 0.001 to 90, preferably 0.005 to 70, most preferably 0.01 to 50% w/w catechins, wherein the oral or topical composition excludes pregnenolone, 4, 5-dihydrofuranodiene-6-one, epoxy santamarin, hydroquinone, longistyline, monacolin K, protoanemonin, N-(2,2,2-tri-fluoro-ethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide, dihydronepetalactone, iridomyrmecin, and dihydroactinidiolide, wherein when the oral or topical composition comprises guggelsterone and epigallocatechin gallate, the oral or topical composition excludes a guggelsterone to epigallocatechin gallate weight ratio of 1 to 28, and wherein when the oral or topical composition comprises sodium dilauramide glutamide lysine, the oral or topical composition excludes 0.3% w/w sodium dilauramide glutamide lysine.

  公开了一种口服或外用组合物，该组合物包含核因子红细胞生成素-2 相关因子 2 激动剂和肝 X 受体激动剂，其中核因子红细胞生成素-2 相关因子 2 激动剂和肝 X 受体激动剂各自的用量对毛发纤维生长产生协同益处，其中口服或外用组合物包含 ≤9% w/w，优选 ≤8% w/w β-谷甾醇，其中当口服或外用组合物包含儿茶素时，口服或外用组合物包含 0.001至90，优选0.005至70，最优选0.其中口服或外用组合物不包括孕烯醇酮、4, 5-二氢呋喃二烯-6-酮、环氧山奈酚、对苯二酚、龙胆紫、莫那可林 K、原橙皮甙、N-(2,2,2-三氟-乙基)-N-[4-(2,2,2-三氟-1-羟基-1-三氟甲基乙基)-苯基]-苯磺酰胺、二氢吡咯内酯、鸢尾霉素和二氢吡咯内酯、其中，当口服或外用组合物包含钩藤甾酮和表没食子儿茶素没食子酸酯时，口服或外用组合物排除钩藤甾酮与表没食子儿茶素没食子酸酯的重量比为1比28，并且其中，当口服或外用组合物包含二月桂酰胺谷酰胺赖氨酸钠时，口服或外用组合物排除0.3% w/w 的二月桂酰胺谷酰胺赖氨酸钠。
• Novel neurotrophic sesquiterpene-neolignans from magnolia obovata
  作者：Yoshiyasu Fukuyama、Yukio Otoshi、Mitsuaki Kodama、Takashi Hasegawa、Hiroshi Okazaki、Masakazu Nagasawa

  DOI：10.1016/s0040-4039(01)93502-6

  日期：1989.1
• FUKUYAMA, YOSHIYASU;OTOSHI, YUKIO;KODAMA, MITSUAKI;HASEGAWA, TAKASHI;OKAZ+, TETRAHEDRON LETT., 30,(1989) N3, C. 5907-5910
  作者：FUKUYAMA, YOSHIYASU、OTOSHI, YUKIO、KODAMA, MITSUAKI、HASEGAWA, TAKASHI、OKAZ+

  DOI：——

  日期：——
• HAIR COMPOSITION
  申请人：Unilever PLC

  公开号：EP3236927A1

  公开（公告）日：2017-11-01
• [EN] THERAPEUTIC RELEASE AGENTS<br/>[FR] AGENTS DE LIBÉRATION THÉRAPEUTIQUES
  申请人：ORGANON NV

  公开号：WO2008100977A2

  公开（公告）日：2008-08-21

  [EN] Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit FAAH activity. Described herein are processes for the preparation of esters of alkylcarbamic acid compounds, compositions that include them, and methods of use thereof.
  [FR] L'inhibition pharmacologique de l'activité de l'amide hydrolase d'acides gras (FAAH) entraîne une augmentation des taux d'amides d'acides gras. L'invention concerne des esters d'acides alkylcarbamiques qui constituent des inhibiteurs de l'activité de la FAAH. Les composés décrits inhibent l'activité de la FAAH. L'invention concerne aussi des procédés de préparation d'esters de composés d'acides alkylcarbamiques, des compositions renfermant ceux-ci et des procédés d'utilisation de celles-ci.